The company announced positive top-line results from EMPA-REG Outcome. This is a long-term clinical trial investigating cardiovascular (CV) outcomes for Jardiance (empagliflozin) in more than 7,000 adults with type 2 diabetes at high risk for CV events. The trial met its primary endpoint and demonstrated superiority of Jardiance, when added to standard of care, in CV risk reduction.
Jardiance is a once-daily pill taken in the morning, used along with diet and exercise, to lower blood sugar in adults with type 2 diabetes. It is not for people with type 1 diabetes or for people with diabetic ketoacidosis (increased ketones in the blood or urine).
Prof. Hans-Juergen Woerle, global vice president medicine, Boehringer Ingelheim said:
The cardiovascular risk reduction Jardiance demonstrated in the EMPA-REG Outcome trial is exciting and we look forward to sharing the full results. Approximately 50% of deaths in people with type 2 diabetes worldwide are caused by cardiovascular disease. Reducing cardiovascular risk is an essential component of diabetes management.
Shares of Eli Lilly were up nearly 5% to $87.88 early Thursday morning. The stock has a consensus analyst price target of $92.06 and a 52-week trading range of $60.58 to $90.18.
ALSO READ: 4 Top Pharma Stocks That Should Outperform Out to 2016
Top Gaining Stocks
Top Losing Stocks